cardiovascular-agents and Urinary-Retention

NXY-059 is a free radical-trapping neuroprotectant that reduces infarct size and preserves brain function in animal models of acute ischemic stroke. Acute ischemic stroke patients receiving NXY-059 may also be exposed to diuretics for treatment of heart failure or hypertension. NXY-059 and furosemide are partly eliminated by active tubular secretion via an organic anion transporter. This double-blind, randomized, crossover, placebo-controlled study investigated whether an infusion of NXY-059 (15 mg/mL) during 12 hours affects the diuretic and saluretic effects of a 30-mg intravenous bolus dose of furosemide (10 mg/mL) administered after 6 hours' infusion, in 13 male and 11 female healthy subjects. The net increase in urine volume and sodium excretion in the interval of 6 to 12 hours was 4.15 L and 178 mmol/L, respectively, during NXY-059 treatment (P = .93) and 4.34 L and 190 mmol/L, respectively, during placebo treatment (P = .54). NXY-059 reduced the renal clearance of furosemide by 19% (P = .019), and furosemide reduced the renal clearance of NXY-059 by 8% (P = .005). NXY-059 was well tolerated.

Topics: Abdominal Pain; Adolescent; Adult; Area Under Curve; Back Pain; Benzenesulfonates; Cardiovascular Agents; Cross-Over Studies; Diuretics; Double-Blind Method; Drug Interactions; Female; Furosemide; Half-Life; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Migraine Disorders; Urinary Retention; Vomiting

Topics: Cardiovascular Agents; Dihydroergotamine; Ergot Alkaloids; Female; Humans; Oxytocics; Postpartum Period; Urinary Retention; Urination Disorders